| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/05/2026 | ±4.2% | -20.1% | under-priced |
| 05/06/2026 | ±6.3% | -9.7% | under-priced |
| 11/06/2025 | ±2.7% | +2.9% | under-priced |
| 08/07/2025 | ±2.5% | +9.5% | under-priced |
| 05/09/2025 | ±3.0% | +20.9% | under-priced |
| 11/08/2024 | ±3.5% | +9.4% | under-priced |
| 08/09/2024 | ±5.1% | -8.8% | under-priced |
| 05/10/2024 | ±3.5% | -6.5% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $1.37 | $802M | $95M |
| Q1 FY2026 | $1.30 | $762M | $91M |
| Q4 FY2025 | $1.43 | $784M | $102M |
| Q3 FY2025 | $1.24 | $706M | $88M |
Insulet Corporation (PODD) reports in 72 days, with the next report estimated for 11/26/2026. Across the last 8 reports, options priced an average ±3.8% earnings move while the stock actually moved 11.0% on average — the market has tended to under-price PODD's earnings risk. Fundamentals into the print: EPS up 328.1% year-over-year, revenue up 23.5%. QuantLogix's live 5-factor engine currently reads PODD as a underweight at 41/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →